Rhamnogalacturonan II is a Toll-like receptor 4 agonist that inhibits tumor growth by activating dendritic cell-mediated CD8þ T cells
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Yeong-Min | - |
dc.contributor.author | Noh, Kyung Tae | - |
dc.contributor.author | Jeong, Young-ll | - |
dc.contributor.author | Jung, In Duk | - |
dc.contributor.author | Kang, Hyun Kyu | - |
dc.contributor.author | Cha, Gil Sun | - |
dc.contributor.author | Lee, Su Jung | - |
dc.contributor.author | Seo, Jong Keun | - |
dc.contributor.author | Kang, Dae Hwan | - |
dc.contributor.author | Hwang, Tae Ho | - |
dc.contributor.author | Lee, Eun Kyung | - |
dc.contributor.author | Kwon, Byungsul | - |
dc.contributor.author | Park, Yeong-Min | - |
dc.date.accessioned | 2023-03-08T21:40:08Z | - |
dc.date.available | 2023-03-08T21:40:08Z | - |
dc.date.issued | 2013 | - |
dc.identifier.issn | 1226-3613 | - |
dc.identifier.issn | 2092-6413 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/64928 | - |
dc.description.abstract | We evaluated the effectiveness of rhamnogalacturonan II (RG-II)-stimulated bone marrow-derived dendritic cells (BMDCs)vaccination on the induction of antitumor immunity in a mouse lymphoma model using EG7-lymphoma cells expressing ovalbumin (OVA). BMDCs treated with RG-II had an activated phenotype. RG-II induced interleukin (IL)-12, IL-1b, tumor necrosis factor-a (TNF-a) and interferon-c (IFN-c) production during dendritic cell (DC) maturation. BMDCs stimulated with RG-II facilitate the proliferation of CD8þ T cells. Using BMDCs from the mice deficient in Toll-like receptors (TLRs), we revealed that RG-II activity is dependent on TLR4. RG-II showed a preventive effect of immunization with OVA-pulsed BMDCs against EG7 lymphoma. These results suggested that RG-II expedites the DC-based immune response through the TLR4signaling pathway. | - |
dc.format.extent | 11 | - |
dc.publisher | 생화학분자생물학회 | - |
dc.title | Rhamnogalacturonan II is a Toll-like receptor 4 agonist that inhibits tumor growth by activating dendritic cell-mediated CD8þ T cells | - |
dc.type | Article | - |
dc.identifier.bibliographicCitation | Experimental and Molecular Medicine, v.45, no.2, pp 1 - 11 | - |
dc.identifier.kciid | ART001743094 | - |
dc.description.isOpenAccess | N | - |
dc.citation.endPage | 11 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 1 | - |
dc.citation.title | Experimental and Molecular Medicine | - |
dc.citation.volume | 45 | - |
dc.publisher.location | 미국 | - |
dc.subject.keywordAuthor | adjuvant | - |
dc.subject.keywordAuthor | dendritic cells | - |
dc.subject.keywordAuthor | rhamnogalacturonan II | - |
dc.subject.keywordAuthor | Toll-like receptor 4 | - |
dc.subject.keywordAuthor | tumor | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.